Bacteriophage Cocktails in the Post-COVID Rehabilitation.
Fedor M ZurabovEkaterina A ChernevskayaNatalia V BeloborodovaAlexander Yu ZurabovMarina V PetrovaMikhail Ya YadgarovValentina M PopovaOleg E FatuevVladislav E ZakharchenkoMarina M GurkovaEkaterina A SorokinaEgor A GlazunovTatiana A KochetovaVictoria V UskevichArtem N KuzovlevAndrey V GrechkoPublished in: Viruses (2022)
Increasing evidence suggests that gut dysbiosis is associated with coronavirus disease 2019 (COVID-19) infection and may persist long after disease resolution. The excessive use of antimicrobials in patients with COVID-19 can lead to additional destruction of the microbiota, as well as to the growth and spread of antimicrobial resistance. The problem of bacterial resistance to antibiotics encourages the search for alternative methods of limiting bacterial growth and restoring the normal balance of the microbiota in the human body. Bacteriophages are promising candidates as potential regulators of the microbiota. In the present study, two complex phage cocktails targeting multiple bacterial species were used in the rehabilitation of thirty patients after COVID-19, and the effectiveness of the bacteriophages against the clinical strain of Klebsiella pneumoniae was evaluated for the first time using real-time visualization on a 3D Cell Explorer microscope. Application of phage cocktails for two weeks showed safety and the absence of adverse effects. An almost threefold statistically significant decrease in the anaerobic imbalance ratio, together with an erythrocyte sedimentation rate (ESR), was detected. This work will serve as a starting point for a broader and more detailed study of the use of phages and their effects on the microbiome.
Keyphrases
- prognostic factors
- coronavirus disease
- antimicrobial resistance
- klebsiella pneumoniae
- sars cov
- pseudomonas aeruginosa
- escherichia coli
- multidrug resistant
- endothelial cells
- microbial community
- systematic review
- respiratory syndrome coronavirus
- wastewater treatment
- chronic kidney disease
- single cell
- single molecule
- end stage renal disease
- mesenchymal stem cells
- cystic fibrosis
- cell therapy
- ejection fraction
- patient reported outcomes
- pluripotent stem cells